ISN Journal summaries on sefaxersen for IgAN and the effect of climate change on kidney disease
Kidney International®
IgA nephropathy (IgAN) involves activation of the complement alternative pathway, contributing to kidney inflammation and disease progression.
In this global, open-label phase 2 trial, patients with biopsy-confirmed IgAN received sefaxersen, an antisense inhibitor of complement factor B, to evaluate its safety and efficacy.
Treatment reduced proteinuria, selectively inhibited alternative pathway activity, and maintained stable kidney function, with an acceptable safety profile. These findings support further investigation of sefaxersen in phase 3 clinical trials.
Kidney International Reports®
Effect of climate change on kidney stones and kidney disease
In this editorial, aligned with World Kidney Day’s focus on the link between climate and kidney health, the authors highlight kidney stones as a visible marker of heat-related kidney stress and summarize evidence connecting rising temperatures, dehydration, and air pollution to kidney injury and disease progression.
The piece calls for greater integration of environmental risk into kidney care practices and more climate-resilient kidney care systems.
